Additionally, combining JAK2 inhibitors with IDH inhibitors (targeting isocitrate dehydrogenase mutations in leukemia) or TKIs (such as imatinib in CML) could provide a comprehensive treatment approach that targets both the JAK-STAT pathway and other critical oncogenic drivers in pediatric leukemia. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.